title: [Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report].
abstract: An 80-year-old man with prostate cancer receiving hormone therapy presented with urinary retention. The computed tomographic scan showed metastases to the lung, liver, and lymph nodes, as well as increased prostate volume. Transurethral resection of the prostate (TURP) was performed, and the resected specimen was pathologically found to be a small cell carcinoma of the prostate. The patient was treated with a combination of carboplatin and irinotecan, and achieved a partial response : size reduction of the prostate and the metastatic lesions, and decreased neuron specific enolase (NSE) level. The chemotherapy with carboplatin and irinotecan is reported to have fewer serious adverse effects, and equivalent efficacy to the cisplatin/etoposide chemotherapy. Therefore, this regimen could also be a treatment option for the patients with small cell carcinoma of the prostate.
authors.affiliation: The Department of Urology, Kansai Electric Power Hospital.
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kimura
authors.affiliation: The Department of Urology, Kansai Electric Power Hospital.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Uegaki
authors.affiliation: The Department of Urology, Kansai Electric Power Hospital.
authors.forename: Teruyoshi
authors.initials: T
authors.lastname: Aoyama
authors.affiliation: The Department of Pathology, Kansai Electric Power Hospital.
authors.forename: Jun
authors.initials: J
authors.lastname: Kawai
authors.affiliation: The Department of Neurology, Kansai Electric Power Hospital.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hamano
authors.affiliation: The Department of Urology, Kansai Electric Power Hospital.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Hashimura
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D007562:Creutzfeldt-Jakob Syndrome / Q000150:complications / Q000175:diagnosis; D017809:Fatal Outcome; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D010751:Phosphopyruvate Hydratase / Q000097:blood; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D020728:Transurethral Resection of Prostate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D000077146:Irinotecan; D016190:Carboplatin; D010751:Phosphopyruvate Hydratase; D002166:Camptothecin